Roche Holding AG (ROP) Moat Analysis

Overview

Roche generated CHF 30,364m of H1 2026 sales, up 6% at constant exchange rates but down 2% in CHF, and CHF 9,671m of IFRS operating profit. Pharmaceuticals contributed 77.8191279% of sales and 92.5691835% of the two positive divisions’ IFRS operating profit; Diagnostics contributed 22.1808721% and 7.4308165%. The pharmaceutical moat is product-specific patent and regulatory exclusivity, not R&D spending itself: the five top growth products generated CHF 11.0bn, while five expired-patent products generated CHF 2.6bn and declined 8% at CER. Diagnostics has the more systemic moat: 6,700+ cobas pro and 3,400+ cobas pure units at year-end 2025 support recurring assay pull-through, while integrated reagents, automation and digital workflow create switching friction. China healthcare pricing reforms and tendering constrain that advantage. PathAI remained an agreed acquisition at the H1 release and is not counted as an existing moat. Roche’s former `ROG` non-voting securities were exchanged for 702,562,700 participation certificates that began trading as `ROP` on 17 March 2026; the record ID, primary ISIN and ticker now reflect that completed change. Roche also has exactly 106,691,000 voting bearer shares (`RO`). At 30 June it reported 0.4m own shares and 12.1m own participation certificates, and an H1 weighted-average basic count of 796m; those rounded figures do not support a more precise current outstanding count. The shareholder pool held 69,318,000 bearer shares, or 64.97% of votes, at year-end 2025. `RHHBY` is a sponsored OTCQX ADR administered by J.P. Morgan, with eight ADRs representing one `ROP`; CUSIP 771195104. LEI 549300U41AUUVOAAOB37 remains issued and entity-active, and SEC CIK 0000889131 remains assigned.